Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

PURPOSE: Limitations of the paclitaxel-doxorubicin-cisplatin (TAP) regimen in the treatment of endometrial cancer include tolerability and cumbersome scheduling. The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. METHODS: GOG0209 was a phase...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:J Clin Oncol
Κύριοι συγγραφείς: Miller, David S., Filiaci, Virginia L., Mannel, Robert S., Cohn, David E., Matsumoto, Takashi, Tewari, Krishnansu S., DiSilvestro, Paul, Pearl, Michael L., Argenta, Peter A., Powell, Matthew A., Zweizig, Susan L., Warshal, David P., Hanjani, Parviz, Carney, Michael E., Huang, Helen, Cella, David, Zaino, Richard, Fleming, Gini F.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2020
Θέματα:
RAPID COMMUNICATIONS
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7676887/
https://ncbi.nlm.nih.gov/pubmed/33078978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.01076
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια